FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3125508314> ?p ?o ?g. }

• W3125508314 endingPage "175628642098672" @default.
• W3125508314 startingPage "175628642098672" @default.
• W3125508314 abstract "Background and aims: Tenecteplase has recently emerged as an alternative thrombolytic agent in acute ischemic stroke (AIS) patients with large vessel occlusion (LVO), possibly superior in achieving early reperfusion compared with alteplase. We aimed to compare the safety and efficacy of intravenous tenecteplase with intravenous alteplase for AIS patients with LVO in everyday clinical practice settings. Methods: We prospectively evaluated patients with AIS due to LVO, treated with intravenous thrombolysis (IVT) with or without mechanical thrombectomy in two tertiary stroke centers. Patients were treated with standard-dose alteplase (0.9 mg/kg) or 0.25 mg/kg tenecteplase. Safety outcomes included prevalence of symptomatic intracranial hemorrhage (sICH) and mortality. Efficacy outcomes included averted thrombectomy, major neurological improvement at 24 h (defined as decrease in baseline NIHSS score of 8 points or greater) and functional status on discharge and on 3 months assessed by modified Rankin Scale (mRS). Results: Nineteen AIS patients with LVO received tenecteplase and 39 received alteplase. We observed a non-significant higher rate of averted thrombectomies (32% versus 18%, p = 0.243) and a non-significant higher rate of sICH (16% versus 5%, p = 0.201) in the tenecteplase group. The rate of 24 h major neurological improvement was higher in the tenecteplase group (64% versus 33%, p = 0.046) but this was marginally attenuated in multivariable analyses (adjusted OR 10.22, 95% CI: 0.73–142.98; p = 0.084). Discharge mRS, 3-months mRS, and 3-month functional independence (mRS scores of 0–2) did not differ ( p > 0.2) between the two groups. The rates of 3-month mortality (11% versus 18%, p = 0.703) were similar in the two groups. No independent association between thrombolytic agent and safety or efficacy outcomes emerged in multivariable regression analyses. Conclusion: The present pilot observational study highlights that AIS patients with LVO treated with 0.25 mg/kg bolus administration of tenecteplase had increased likelihood to achieve early neurological improvement compared with AIS patients treated with alteplase, but this association was attenuated after adjustment for potential confounders. There were no significant differences in 3-month functional or safety outcomes between the two groups. This preliminary real-world observation requires independent confirmation in larger, multicenter studies." @default.
• W3125508314 created "2021-02-01" @default.
• W3125508314 creator A5004293145 @default.
• W3125508314 creator A5019953858 @default.
• W3125508314 creator A5020562135 @default.
• W3125508314 creator A5023762588 @default.
• W3125508314 creator A5024296707 @default.
• W3125508314 creator A5024359683 @default.
• W3125508314 creator A5037648017 @default.
• W3125508314 creator A5040041979 @default.
• W3125508314 creator A5041498262 @default.
• W3125508314 creator A5049558076 @default.
• W3125508314 creator A5064317922 @default.
• W3125508314 creator A5067071550 @default.
• W3125508314 creator A5079405221 @default.
• W3125508314 date "2021-01-01" @default.
• W3125508314 modified "2023-09-27" @default.
• W3125508314 title "Real-world comparative safety and efficacy of tenecteplase <i>versus</i> alteplase in acute ischemic stroke patients with large vessel occlusion" @default.
• W3125508314 cites W1943911105 @default.
• W3125508314 cites W1972869299 @default.
• W3125508314 cites W1986999526 @default.
• W3125508314 cites W2000028217 @default.
• W3125508314 cites W2002874591 @default.
• W3125508314 cites W2025001008 @default.
• W3125508314 cites W2105402180 @default.
• W3125508314 cites W2106076655 @default.
• W3125508314 cites W2111255873 @default.
• W3125508314 cites W2164655776 @default.
• W3125508314 cites W2171165037 @default.
• W3125508314 cites W2595483828 @default.
• W3125508314 cites W2613648120 @default.
• W3125508314 cites W2740053016 @default.
• W3125508314 cites W2772400303 @default.
• W3125508314 cites W2789663956 @default.
• W3125508314 cites W2802880180 @default.
• W3125508314 cites W2810116517 @default.
• W3125508314 cites W2886777603 @default.
• W3125508314 cites W2905585525 @default.
• W3125508314 cites W2911196419 @default.
• W3125508314 cites W2916543290 @default.
• W3125508314 cites W2982303713 @default.
• W3125508314 cites W3007171003 @default.
• W3125508314 cites W3042465754 @default.
• W3125508314 cites W4253127896 @default.
• W3125508314 cites W4255683973 @default.
• W3125508314 doi "https://doi.org/10.1177/1756286420986727" @default.
• W3125508314 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7809628" @default.
• W3125508314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33488774" @default.
• W3125508314 hasPublicationYear "2021" @default.
• W3125508314 type Work @default.
• W3125508314 sameAs 3125508314 @default.
• W3125508314 citedByCount "19" @default.
• W3125508314 countsByYear W31255083142021 @default.
• W3125508314 countsByYear W31255083142022 @default.
• W3125508314 countsByYear W31255083142023 @default.
• W3125508314 crossrefType "journal-article" @default.
• W3125508314 hasAuthorship W3125508314A5004293145 @default.
• W3125508314 hasAuthorship W3125508314A5019953858 @default.
• W3125508314 hasAuthorship W3125508314A5020562135 @default.
• W3125508314 hasAuthorship W3125508314A5023762588 @default.
• W3125508314 hasAuthorship W3125508314A5024296707 @default.
• W3125508314 hasAuthorship W3125508314A5024359683 @default.
• W3125508314 hasAuthorship W3125508314A5037648017 @default.
• W3125508314 hasAuthorship W3125508314A5040041979 @default.
• W3125508314 hasAuthorship W3125508314A5041498262 @default.
• W3125508314 hasAuthorship W3125508314A5049558076 @default.
• W3125508314 hasAuthorship W3125508314A5064317922 @default.
• W3125508314 hasAuthorship W3125508314A5067071550 @default.
• W3125508314 hasAuthorship W3125508314A5079405221 @default.
• W3125508314 hasBestOaLocation W31255083141 @default.
• W3125508314 hasConcept C126322002 @default.
• W3125508314 hasConcept C127413603 @default.
• W3125508314 hasConcept C2776268601 @default.
• W3125508314 hasConcept C2776572282 @default.
• W3125508314 hasConcept C2779095551 @default.
• W3125508314 hasConcept C2779581417 @default.
• W3125508314 hasConcept C2780645631 @default.
• W3125508314 hasConcept C2780931571 @default.
• W3125508314 hasConcept C2909817843 @default.
• W3125508314 hasConcept C3020199598 @default.
• W3125508314 hasConcept C42219234 @default.
• W3125508314 hasConcept C500558357 @default.
• W3125508314 hasConcept C541997718 @default.
• W3125508314 hasConcept C71924100 @default.
• W3125508314 hasConcept C78519656 @default.
• W3125508314 hasConceptScore W3125508314C126322002 @default.
• W3125508314 hasConceptScore W3125508314C127413603 @default.
• W3125508314 hasConceptScore W3125508314C2776268601 @default.
• W3125508314 hasConceptScore W3125508314C2776572282 @default.
• W3125508314 hasConceptScore W3125508314C2779095551 @default.
• W3125508314 hasConceptScore W3125508314C2779581417 @default.
• W3125508314 hasConceptScore W3125508314C2780645631 @default.
• W3125508314 hasConceptScore W3125508314C2780931571 @default.
• W3125508314 hasConceptScore W3125508314C2909817843 @default.
• W3125508314 hasConceptScore W3125508314C3020199598 @default.
• W3125508314 hasConceptScore W3125508314C42219234 @default.
• W3125508314 hasConceptScore W3125508314C500558357 @default.
• W3125508314 hasConceptScore W3125508314C541997718 @default.

• next